Will QuidelOrtho’s (QDEL) Rapid Respiratory Test Raise Its Profile in Point-of-Care Diagnostics?

• QuidelOrtho Corporation recently announced the launch of the QUICKVUE Influenza + SARS Test, a rapid, CLIA-waived diagnostic immunoassay for professional healthcare settings in the United States, offering simultaneous detection of influenza A, influenza B, and SARS-CoV-2 antigens with results in as fast as 10 minutes.
• This expansion of the QUICKVUE portfolio gives healthcare providers a more efficient visual tool to differentiate between respiratory infections at the point of care, further reinforcing QuidelOrtho’s presence in decentralized testing solutions.
• We'll examine how the introduction of this triple detection test potentially enhances QuidelOrtho’s competitive edge and long-term diagnostic portfolio outlook.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

QuidelOrtho Investment Narrative Recap

QuidelOrtho’s future depends on whether it can successfully reposition its diagnostics portfolio as pandemic-era COVID testing demand sharply declines and competition intensifies across point-of-care markets. The launch of the QUICKVUE Influenza + SARS Test directly addresses the urgent need for new revenue drivers, offering an accessible, multi-pathogen assay for respiratory infections, but its near-term impact is unlikely to fully offset lost high-margin COVID testing revenues, which remain the largest risk to profitability going forward.

Among recent announcements, the new Certified Analyzer Program, aimed at broadening access to VITROS analyzers in rural hospitals, speaks to efforts to diversify customer reach and stabilize revenues by improving access to core diagnostic solutions, complementing the company’s push to expand its point-of-care offerings and enhance recurring revenue amid shifting healthcare priorities.

However, despite new launches, investors should not overlook lingering concerns around post-pandemic normalization and the ongoing decline in COVID-related revenue as...

Read the full narrative on QuidelOrtho (it's free!)

QuidelOrtho's outlook anticipates $3.0 billion in revenue and $17.2 million in earnings by 2028. This is based on a projected annual revenue growth rate of 2.6% and an earnings increase of $483.6 million from current earnings of -$466.4 million.

Uncover how QuidelOrtho's forecasts yield a $40.33 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Community estimates from Simply Wall St members span a wide fair value range for QuidelOrtho, from US$40.33 to US$87.69, based on three different analyses. With persistent revenue headwinds as COVID testing fades, your view may differ, explore more perspectives to form a balanced outlook.

Explore 3 other fair value estimates on QuidelOrtho - why the stock might be worth just $40.33!

Build Your Own QuidelOrtho Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your QuidelOrtho research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free QuidelOrtho research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate QuidelOrtho's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com